Zacks Research Predicts Bruker's Q2 Earnings (NASDAQ:BRKR)

Bruker Corporation (NASDAQ:BRKR - Free Report) - Analysts at Zacks Research reduced their Q2 2025 earnings estimates for Bruker in a research note issued to investors on Thursday, July 17th. Zacks Research analyst R. Department now expects that the medical research company will earn $0.42 per share for the quarter, down from their prior estimate of $0.43. The consensus estimate for Bruker's current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker's FY2027 earnings at $3.04 EPS.

Several other research firms have also recently issued reports on BRKR. Stifel Nicolaus cut their price target on shares of Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a report on Thursday, May 8th. Wells Fargo & Company cut their price target on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a report on Thursday, April 17th. Citigroup cut shares of Bruker from a "strong-buy" rating to a "hold" rating and cut their price target for the stock from $50.00 to $40.00 in a report on Thursday, May 22nd. Bank of America lowered their target price on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Finally, The Goldman Sachs Group lowered their target price on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Six research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $52.89.

Bruker Trading Down 3.9%

NASDAQ BRKR opened at $40.55 on Monday. The stock has a market capitalization of $6.14 billion, a P/E ratio of 77.98, a P/E/G ratio of 2.73 and a beta of 1.18. Bruker has a 52-week low of $34.10 and a 52-week high of $72.94. The firm has a 50-day moving average price of $39.43 and a 200 day moving average price of $44.79. The company has a quick ratio of 0.74, a current ratio of 1.57 and a debt-to-equity ratio of 1.13.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.01. The firm had revenue of $801.40 million during the quarter, compared to analysts' expectations of $763.83 million. Bruker had a net margin of 2.31% and a return on equity of 19.47%. The firm's revenue for the quarter was up 11.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.53 earnings per share.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Monday, June 16th were given a $0.05 dividend. The ex-dividend date was Monday, June 16th. This represents a $0.20 annualized dividend and a dividend yield of 0.49%. Bruker's dividend payout ratio is presently 38.46%.

Insider Activity at Bruker

In other Bruker news, CEO Frank H. Laukien purchased 2,608 shares of the stock in a transaction dated Friday, June 6th. The shares were acquired at an average cost of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the transaction, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at $1,475,408,879.56. This trade represents a 0.01% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 27.30% of the stock is owned by corporate insiders.

Institutional Trading of Bruker

Several large investors have recently modified their holdings of the business. London Co. of Virginia grew its position in shares of Bruker by 78.4% in the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock valued at $245,820,000 after purchasing an additional 1,843,294 shares during the last quarter. Sculptor Capital LP grew its position in shares of Bruker by 51.6% in the first quarter. Sculptor Capital LP now owns 2,598,438 shares of the medical research company's stock valued at $108,459,000 after purchasing an additional 884,423 shares during the last quarter. Brown Advisory Inc. grew its position in shares of Bruker by 18.9% in the first quarter. Brown Advisory Inc. now owns 2,410,137 shares of the medical research company's stock valued at $100,599,000 after purchasing an additional 383,425 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Bruker by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company's stock valued at $118,081,000 after purchasing an additional 20,273 shares during the last quarter. Finally, FIL Ltd grew its position in shares of Bruker by 262.3% in the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock valued at $114,978,000 after purchasing an additional 1,420,102 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.